Ratings BioLargo, Inc.

Equities

BLGO

US09065A1007

Market Closed - OTC Markets 03:25:44 2024-04-26 pm EDT 5-day change 1st Jan Change
0.3525 USD +2.78% Intraday chart for BioLargo, Inc. +3.80% +109.82%

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Commodity Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
+109.82% 104M -
+5.14% 103B
A-
-5.63% 63.04B
A-
+39.52% 39.06B
B
+12.91% 37.58B
B
+7.41% 33.24B
A-
+6.85% 19.22B
B-
+12.86% 16.83B
C+
+16.93% 14.96B
B-
+7.73% 15.03B
B
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. BLGO Stock
  4. Ratings BioLargo, Inc.